Receptor subtype-selective binding and functional assays — typically comparing synephrine's potency at beta-1, beta-2, and beta-3 adrenergic receptor subtypes using cAMP accumulation or radioligand displacement methods — are used to characterise its relative selectivity profile. This research is conducted in the context of broader structure-activity work on phenylethanolamine compounds, comparing synephrine's substitution pattern to other adrenergic agonists with different subtype selectivity to map which structural features drive beta-3 preference.

Solution format at a defined concentration (50 mg/ml) allows researchers to administer precise volumetric doses without requiring on-site weighing and dissolution, reducing a source of dosing variability in protocols requiring repeated or time-sensitive administration. This format is particularly useful in rodent pharmacokinetic studies and in vitro dose-response work where rapid, accurate dilution series preparation is required.

Synephrine shares the core phenylethanolamine scaffold with related compounds in this structural class, differing in the specific pattern and position of hydroxyl and methyl substituents on the aromatic ring and amine nitrogen. These structural differences are the basis for comparative structure-activity relationship studies examining how substitution pattern influences adrenergic receptor subtype selectivity and binding affinity across the phenylethanolamine compound series.